Nyxoah SA
Develops hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA).
NYXH | BR
Overview
Corporate Details
- ISIN(s):
- BE0974358906
- LEI:
- 5493002O1ESKZ18OXR80
- Country:
- Belgium
- Address:
- Rue Edouard Belin 12, 1435 Mont-Saint-Guibert
- Website:
- https://www.nyxoah.com/
- Sector:
- Manufacturing
Description
Nyxoah SA is a medical technology company focused on the development and commercialization of solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, a hypoglossal neurostimulation (HNS) therapy designed for patients with moderate to severe OSA. The system features a patient-centered, leadless, and battery-free implantable stimulator. It functions by providing bilateral stimulation to the hypoglossal nerve, which controls tongue muscles, to maintain an open airway during sleep.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-30 18:00 |
Project Nuit (PIPE) - Special Board Report art 7_198 7_179 7_191 and 7_193_E (F…
|
English | 251.5 KB | ||
| 2023-03-30 18:00 |
Project Nuit (PIPE) - Special Board Report art 7_198 7_179 7_191 and 7_193_FR (…
|
French | 253.8 KB | ||
| 2023-03-27 22:05 |
2023 03 27 22u05 english-atm-final.pdf
|
English | 153.7 KB | ||
| 2023-03-27 22:05 |
2023 03 27 22u05 french-atm-final.pdf
|
French | 152.2 KB | ||
| 2023-03-23 21:05 |
2023 03 23 21u05 english-pipe-press-release-final.pdf
|
English | 230.7 KB | ||
| 2023-03-23 21:05 |
2023 03 23 21u05 french-pipe-press-release-final.pdf
|
French | 158.0 KB | ||
| 2023-03-22 21:05 |
231545_Nyxoah Annual report 2022_ENG_FINAL.pdf
|
English | 2.0 MB | ||
| 2023-03-22 21:05 |
231545_Nyxoah Annual report 2022_FR_FINAL.pdf
|
French | 2.3 MB | ||
| 2023-03-22 21:05 |
nyxoah-2022-12-31-fr.zip
|
French | 3.1 MB | ||
| 2023-03-22 21:05 |
nyxoah-2022-12-31-fr.xhtml
|
French | 6.5 MB | ||
| 2023-03-22 21:05 |
2023 03 22 21u05 english-q4-2022-earnings-pr-final.pdf
|
English | 285.8 KB | ||
| 2023-03-22 21:05 |
2023 03 22 21u05 french-q4-2022-earnings-pr-final.pdf
|
French | 284.6 KB | ||
| 2023-03-06 07:30 |
2023 03 06 7u30 english-nyxoah-announces-a-clinical-update.pdf
|
English | 177.0 KB | ||
| 2023-03-06 07:30 |
2023 03 06 7u30 french-nyxoah-announces-a-clinical-update.pdf
|
French | 180.2 KB | ||
| 2022-12-29 22:30 |
2022 12 29 - Press release - Number of shares (ENG).pdf
|
English | 154.3 KB |
Automate Your Workflow. Get a real-time feed of all Nyxoah SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nyxoah SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nyxoah SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-19 | Laurette Renard | Close relation | Sell | 5,000 | 39,000.00 EUR |
| 2024-09-05 | Hambrecht Jürgen | Board | Sell | 980,000 | 6,840,400.00 EUR |
| 2024-09-05 | JH Capital GmbH | Close relation | Buy | 980,000 | 6,840,400.00 EUR |
| 2024-01-25 | Tompkins Patrick | Executive member | Buy | 2,000 | 18,020.00 USD |
| 2023-12-28 | Onkelinx Bruno | Executive member | Buy | 470 | 2,035.10 EUR |
| 2023-08-18 | Moreau Loïc | Executive member | Buy | 6,427 | 48,416.52 EUR |
| 2023-08-14 | Moreau Loïc | Executive member | Buy | 3,800 | 28,697.60 EUR |
| 2023-08-11 | Moreau Loïc | Executive member | Buy | 3,000 | 21,957.60 EUR |
| 2023-07-04 | Wildman Ventures LLC | Board | Buy | 25,000 | N/A |
| 2023-07-02 | Gianello Pierre | Board | Buy | 25,000 | N/A |
Peer Companies
